GlassScriptPhysician profile
Reid Waldman
NPI 1720514151
$6,897.45
in general payments reported to CMS, 2019-2025
22 companies · $905 in 2025
The $905 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.06 · 2021: $1,869 · 2022: $1,296 · 2023: $1,602 · 2024: $1,209 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,628 · Education: $87.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,628.31 |
| Education | $87.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,019.69 | 2021-2025 | Skyrizi, Rinvoq |
| Almirall LLC | $1,699.46 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $576.63 | 2022-2025 | Sotyktu |
| Ucb, INC. | $383.72 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $347.85 | 2022-2025 | |
| Incyte Corporation | $332.07 | 2022-2025 | Opzelura |
| Genzyme Corporation | $287.16 | 2022-2024 | |
| Dermavant Sciences, INC. | $274.23 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $271.73 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $180.02 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $89.39 | 2024-2025 | |
| Galderma Laboratories, L.P. | $80.42 | 2022-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $78.15 | 2024 | Taltz, Olumiant, Ebglyss |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Amgen INC. | $39.00 | 2021-2024 | Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $36.73 | 2023 | |
| Organon LLC | $29.13 | 2025 | Vtama |
| Fresenius Kabi USA, LLC | $25.54 | 2023 | |
| Botanix Sb INC | $22.43 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $20.11 | 2024 | Zoryve |
| Genentech USA, INC. | $17.06 | 2019 | |
| Leo Pharma INC. | $14.93 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reid Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.